Thalia Therapeutics - Grant of Director Share Options

Thalia Therapeutics

23/07/2026 09:25

RNS Number : 5782N
  
Thalia Therapeutics PLC
  
23 July 2026
  
 


23 July 2026
 
Thalia Therapeutics plc
 
("Thalia" or the "Company")
 
Grant of Director Share Options
 
Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that it has granted options over a total of 200,000,000 ordinary shares in the Company (the "Options") to certain directors under the Company's share option plan.
 
Following the Annual General Meeting and completion of the acquisition of Sanmirna Therapeutics Inc (the "Acquisition") as announced on 17 July 2026, the Board believes that the grant of Options provides an appropriate long-term incentive, aligning the interests of the Directors with those of shareholders and supporting the delivery of the Company's strategic and commercial objectives.
 
Key terms of the Options
·      Total of 200,000,000 Options granted to five directors
·      Exercise price of 0.6 pence per ordinary share, being equal to the recent subscription price
·      Ten-year term from the date of grant
·      50% (100,000,000) of the Options vest subject to continued appointment, in three equal tranches on the first, second and third anniversaries of the grant date, being 20 July 2026
·      The remaining 50% (100,000,000) vest only upon achievement of share price performance targets:
o  25% of the total award vests if the Company's share price reaches 1.2 pence per share, representing a doubling of the recent subscription price; and
o  25% of the total award vests if the Company's share price reaches 1.8 pence per share, representing a tripling of the recent subscription price
 
The Options represent approximately 11.25% of the Company's current issued share capital (excluding the new option shares). On a fully diluted basis, including outstanding convertible loan notes, warrants and these Options, the awards represent approximately 7.5% of the Company's enlarged fully diluted share capital, prior to the issue of any future milestone payments under the share purchase agreement pertaining to the Acquisition.
 
Director option grants
 




Director


Position


Number of Options




David H Solomon


Chief Executive Officer


50,000,000




Christopher Britten


Non-Executive Chair


45,000,000




Luke Cairns


Executive Director


45,000,000




Alastair Smith


Non-Executive Director


35,000,000




Michael Palfreyman


Non-Executive Director


25,000,000




 
The table at the end of this announcement, which is provided in accordance with the requirements of the UK Market Abuse Regulation, provides further details.
 
- Ends -
 
For more information please contact:
 




Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer


 
Via Thalia Investor Hub
https://investors.thaliatx.com/link/exow8y




SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


Tel: +44 (0)20 3470 0470




Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker/Guy McDougall 


Tel: +44 (0)20 3657 0050




Northstar Communications Limited
Investor relations and Communications
Sarah Hollins
 
Cohesion Bureau
Investor relations and Communications
Mary-Ann Chang


Tel: +44 (0)20 7183 2463
 
 
 
 
Tel: +44 (0)7483 284853
 
 




About Thalia Therapeutics plc
 
Thalia Therapeutics is a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat disease at its source by silencing or modifying the genes that cause or contribute to it.
 
Our clinical-stage programme miRisten is a microRNA therapeutic in development for Acute Myeloid Leukaemia (AML). Alongside this, our preclinical bispecific siRNA programme is being developed as a potentially long-acting treatment for atherosclerotic cardiovascular disease by addressing two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
 
For further information visit www.thaliatx.com
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 
 




1


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


1.    David Solomon (Chief Executive)
2.    Chris Britten (Non-Executive Chair)
3.    Luke Cairns (Executive Director)
4.    Alastair Smith (Non-Executive Director)
5.    Michael Palfreyman (Non-Executive Director)
 




2


Reason for the notification




a)


Position/status


See 1 a)




b)
 


Initial notification /Amendment


Initial notification
 
 




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Thalia Therapeutics plc
 
 




b)


LEI


213800OIN8T68PM7HK77
 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




a)
 


Description of the financial instrument, type of instrument
 
Identification code


Options over Ordinary Shares of 0.4p each  
 
 
 
Identification code (ISIN) for Thalia Therapeutics plc ordinary shares: GB00BYW8QM32
 




b)


Nature of the transaction


Grant of options
 
 




c)


Price(s) and volume(s)






Name


Exercise Price


Volume(s)




1.            David Solomon
2.            Chris Britten
3.            Luke Cairns
4.            Alastair Smith
5.            Michael Palfreyman


0.6 pence
0.6 pence
0.6 pence
0.6 pence
0.6 pence
 


50,000,000
45,000,000
45,000,000
35,000,000
25,000,000
 









d)


Aggregated information
- Aggregated volume
- Price


 
n/a




e)


Date of the transaction


20 July 2026




f)


Place of the transaction


Outside a trading venue




 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHRJMPTMTTTMBF